What is the success rate of Arimidex?
•
5 min read
Studies have consistently shown that Arimidex significantly reduces the risk of breast cancer recurrence in postmenopausal women with hormone-receptor-positive disease. In one major trial (ATAC), patients on Arimidex had an 89.4% disease-free survival rate at three years, compared to 87.4% for those on tamoxifen. Understanding the specific success rate of Arimidex depends on the type of cancer and treatment context.
